Test will specifically adjust for isatuximab-induced interference in complete response assessment of multiple myeloma patients Paris, France, January 7, 2020 – Sebia (Lisses, France), a world leader ...

Sebia, announces the launch of its serum based Minimal Residual Disease (MRD) test for monitoring in multiple myeloma. M-inSight®is a Laboratory Developed Test (LDT) being offered by Corgenix, College ...

Paris, France, December 9, 2020 – Sebia, a world leader in multiple myeloma diagnostics and monitoring, today announces a license agreement with the Erasmus University Medical Center (Erasmus MC) in ...

Lisses-headquartered Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune ...

The strategic acquisition reinforces Sebia's global leadership in specialty diagnostics LISSES, France, June 30, 2021 /PRNewswire/ -- Sebia, a leading provider of clinical protein electrophoresis ...

Test is based on quantifying free alpha globin chains in patient blood. The French National Institute of Health and Medical Research (Inserm) is teaming up with in vitro diagnostics firm Sebia to ...

Hemoglobinopathies are inherited single-gene disorders leading to production of abnormal hemoglobin or low hemoglobin. Approximately 7% of the global population are carriers and 2.7 per 1000 ...

CDPQ to acquire significant minority stake in Sebia, a global leader in the medical diagnostics sector, from Astorg and Montagu PARIS and MONTRÉAL, Aug. 10, 2017 /CNW Telbec/ – Astorg and Montagu, two ...

Cinven's buyout of Swedish blood test systems manufacturer Phadia in 2007 had headline leverage of 9.5 times, bankers said at the time, rising as high as 12.5 times including capital expenditure.

LISSES, France, June 30, 2021 /PRNewswire/ -- Sebia, a leading provider of clinical protein electrophoresis equipment and reagents for diabetes and oncology detection, today announced the acquisition ...